IBC Life Sciences

Daiichi Sankyo Co to deliver keynote presentation at IBC's Drug Discovery & Development week in Boston, MA.

Tuesday, August 4 at 5:20pm

Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market
The current challenge for Japanese pharmaceutical companies to stay competitive in the global marketplace is to expand product offerings and sales and increase R&D and clinical development capabilities in the U.S., Europe and other markets outside of Japan. This presentation will discuss Daiichi Sankyo's vision and strategy for transforming itself from a Japan-based pharmaceutical company to a truly global pharmaceutical player. Recent implementations of this strategy including the incorporation of Ranbaxy (India) and U3 Pharma (Germany) into the Daiichi Sankyo family will be discussed.

June 9 (Bloomberg) -- Daiichi Sankyo Co. is seeking biotechnology acquisitions in Europe to advance cancer research, and will use $5 billion in funds to enter new markets and fill gaps in its heart-drug portfolio. Read the full article at Bloomberg